<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2017092036203N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-11-01</date_registration>
      <primary_sponsor>Private</primary_sponsor>
      <public_title>The effect of laser therapy on the healing of human palatal wound after free gingival graft surgery</public_title>
      <acronym></acronym>
      <scientific_title>Effects of Ga Al As 940nm low-level laser therapy  on the healing of human  palatal mocusa after free gingival graft surgery:a clinical trial study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>16</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/27132</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Palatal wound after free gingival graft surgery.</hc_freetext>
      <i_freetext>Intervention 1: The patients allocated for the test group will receive the&#13;
following protocol for laser application: A GaAlAs laser will be used for irradiation at a wavelength of 940 nm, an intensity that had been previously calibrated by the manufacturer.(Ezlase; Biolase Technology Inc., Irvine,CA, USA). The wounds of each experimental group receive laser stimulation at doses of 5J/cm2. The power output is maintained at a constant 0.21 W in the continuous-wave (cw) mode; The spot size is 1.26 cm2, the total energy dose per session is 6.3 J, and powerdensity is 0.16 W/cm2. Laser energy will be applied via a 400 micron optical fiber. The optical fiber is positioned at a&#13;
distance of approximately 5 mm proximal to the wound,&#13;
and the irradiation time is 30 s. The experimental&#13;
groups will receive their first dose of irradiation immediately after surgery and within ten days, one day apart following the surgery for a total of 5 sessions. Intervention 2: The patients allocated&#13;
to the control group will receive sham irradiation. For&#13;
this, rubber protection is placed at the tip of the&#13;
laser device, which don't allow the light to reach the&#13;
tissue. The applications will be performed by a different&#13;
operator  from the one who measure the study&#13;
parameters.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ghazal Morshedzade Tehrani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dentistry faculty of Tehran University of Medical Sciences, North Karegar  St, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8888 3575</telephone>
        <email>ghzlmt@gmail.com</email>
        <affiliation>Dentistry Faculty of Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Hoori Asl Roosta</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Periodontology, Third floor, Dentistry Faculty of Tehran University of Medical Sciences, North Karegar  St, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 912 547 0342</telephone>
        <email>h-aslroosta@sina.tums.ac.ir</email>
        <affiliation>Dentistry Faculty of Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: patents aged between 20 and 70 years old, systemically healthy, keratinized tissue width&lt;1mm , Full Mouth Plaque Score (FMPS)&lt;20%, Full Mouth Bleeding Score (FMBS)&lt;20%, absence of pathological or morphological alterations in the palatal region (donor site). &#13;
Exclusion criteria: presence of gag reflex, smoking, presence of proximal bone loss, loss of sensation in palatal mucosa, tooth mobility and/or occlusal trauma in corresponding area, excessive forces (e.g., mechanical forces from orthodontics and traumatic occlusions), systematic diseases that would contraindicate periodontal surgery or interfere with tissue healing such as diabetes, chronic high dose steroid therapy, history of radiation or immuno-suppressive therapy, pregnancy, lactation, gastro-intestinal problems, hyper sensitivity to impression materials, history of drug therapies that are known to interfere with healing or cause gingival enlargement, and patients not complying with postoperative protocols and/or attending their visits irregularly.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K13.7</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other and unspecified lesions of oral mucosa</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The patients allocated for the test group will receive the&#13;
following protocol for laser application: A GaAlAs laser will be used for irradiation at a wavelength of 940 nm, an intensity that had been previously calibrated by the manufacturer.(Ezlase; Biolase Technology Inc., Irvine,CA, USA). The wounds of each experimental group receive laser stimulation at doses of 5J/cm2. The power output is maintained at a constant 0.21 W in the continuous-wave (cw) mode; The spot size is 1.26 cm2, the total energy dose per session is 6.3 J, and powerdensity is 0.16 W/cm2. Laser energy will be applied via a 400 micron optical fiber. The optical fiber is positioned at a&#13;
distance of approximately 5 mm proximal to the wound,&#13;
and the irradiation time is 30 s. The experimental&#13;
groups will receive their first dose of irradiation immediately after surgery and within ten days, one day apart following the surgery for a total of 5 sessions.</i_keyword>
      <i_keyword>The patients allocated&#13;
to the control group will receive sham irradiation. For&#13;
this, rubber protection is placed at the tip of the&#13;
laser device, which don't allow the light to reach the&#13;
tissue. The applications will be performed by a different&#13;
operator  from the one who measure the study&#13;
parameters.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Remaining Wound Area. Timepoint: On the day of surgery and on the 7th , 14th, 28th, 60th days after surgery. Method of measurement: Image J software (mm2).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pain. Timepoint: The first 10 days after surgery. Method of measurement: Questionaire (VAS).</sec_outcome>
      <sec_outcome>Epithelialization. Timepoint: On the 7th , 14th, 28th, 60th days after surgery. Method of measurement: By means of bubble formation after dripping hydrogen peroxide (3%) to the wound surface (total, partial or none).</sec_outcome>
      <sec_outcome>Secondary bleeding. Timepoint: The first 10 days after surgery. Method of measurement: Questionaire.</sec_outcome>
      <sec_outcome>Colour Match (brightness parameters). Timepoint: On the 7th , 14th, 28th, 60th days after surgery. Method of measurement: Adobe photoshop software.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Private</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-09-10</approval_date>
        <contact_name>Ethics Committee of Dentistry Faculty of Tehran University of Medical Sciences</contact_name>
        <contact_address>Dentistry Faculty of Tehran University of Medical Sciences, North Karegar  St, Tehran, Iran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
